{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:13:52Z","timestamp":1793106832560,"version":"4.5.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To validate the American Joint Committee on Cancer (AJCC) 9th edition M1-stage subdivision for de novo metastatic nasopharyngeal carcinoma (DM-NPC) and explore preliminary evidence for a refined classification using 18F-FDG positron emission tomography\/computed tomography (PET\/CT)-derived metastatic burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>A retrospective cohort of 185 DM-NPC patients diagnosed between 2000 and 2022, who underwent pretreatment 18F-FDG PET\/CT, was analyzed. Recursive partitioning analysis (RPA) identified prognostic cutoffs for metastatic lesions. Survival outcomes were compared between AJCC 9th edition M1 subgroups (M1a: \u22643 lesions; M1b: &gt;3 lesions) and a redefined PET-based classification (Rd-M1a: single-organ, \u22644 lesions; Rd-M1b: &gt;5 lesions or multiorgan).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Patients with single-organ metastases and \u22644 lesions showed potentially superior overall survival (OS) (2-y OS: 60.4% vs. 29.0%; 3-y OS: 46.2% vs. 19.6%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Higher metastatic burden (&gt;5 lesions) was independently associated with worse OS (HR: 1.81; 95% CI: 1.24\u20132.64;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.002). The redefined classification suggested better prognostic discrimination than the AJCC 9th edition (C-index: 0.594 vs. 0.562; AUC at 36\u00a0mo: 0.649 vs. 0.598). Patients classified as Rd-M1b had a significantly unfavorable OS compared with those in the Rd-M1a group (HR: 2.02, 95% CI: 1.39\u20132.92;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These preliminary findings suggest that 18F-FDG PET\/CT may enhance M1-stage stratification by quantifying metastatic burden and distribution in patients with DM-NPC, potentially offering improved prognostic accuracy. However, as a single-institution retrospective study, external validation is essential to confirm these observations and guide personalized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006292","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:00:52Z","timestamp":1770141652000},"page":"195-202","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Refining M1-Stage Stratification in De Novo Metastatic Nasopharyngeal Carcinoma Using 18F-FDG PET\/CT"],"prefix":"10.1097","volume":"51","author":[{"given":"Sean Hsiang-Ting","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Ming","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Keelung Chang Gung Memorial Hospital, Keelung"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0910-7803","authenticated-orcid":false,"given":"Kang-Shing","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tu-Shen Chang Gung Memorial Hospital, New Taipei"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8725-6209","authenticated-orcid":false,"given":"Po-Hung","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8414-595X","authenticated-orcid":false,"given":"Li-Ang","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan"},{"name":"School of Medicine, College of Life Sciences and Medicine, National Tsing Hua University, Hsinchu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiang-Fu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan"},{"name":"Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-9396","authenticated-orcid":false,"given":"Chung-Jan","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2910-1393","authenticated-orcid":false,"given":"Eric Yi-Liang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan"},{"name":"Graduate Institute of Clinical Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1777-9578","authenticated-orcid":false,"given":"Kai-Ping","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Wen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Hsu","family":"Lien","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan-Jen","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Joy","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Tung-Chieh","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan"},{"name":"Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"R1-20260203","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260203","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"R3-20260203","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jamaoncol.2024.4354","article-title":"Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification","volume":"10","author":"Pan","year":"2024","journal-title":"JAMA Oncol"},{"key":"R4-20260203","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3390\/cancers16050918","article-title":"Precision medicine for nasopharyngeal cancer\u2014a review of current prognostic strategies","volume":"16","author":"Suryani","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R5-20260203","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1016\/j.ijrobp.2021.07.1337","article-title":"Stereotactic body radiation therapy for the first-line comprehensive treatment of oligometastatic nasopharyngeal carcinoma: a prospective, single-arm, phase II trial","volume":"111","author":"Wu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R6-20260203","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijrobp.2004.09.057","article-title":"Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography","volume":"62","author":"Chang","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20260203","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cpet.2021.12.006","article-title":"PET\/CT: Nasopharyngeal cancers","volume":"17","author":"Xie","year":"2022","journal-title":"PET Clinics"},{"key":"R8-20260203","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00259-008-0918-7","article-title":"Staging of untreated nasopharyngeal carcinoma with PET\/CT: comparison with conventional imaging work-up","volume":"36","author":"Ng","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-20260203","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.oraloncology.2012.08.011","article-title":"Pretreatment (18)F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma","volume":"49","author":"Hung","year":"2013","journal-title":"Oral Oncol"},{"key":"R10-20260203","first-page":"405","article-title":"The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx","volume":"46","author":"Yen","year":"2005","journal-title":"J Nucl Med"},{"key":"R11-20260203","doi-asserted-by":"crossref","first-page":"109769","DOI":"10.1016\/j.radonc.2023.109769","article-title":"The impact of local control on widespread progression and survival in oligometastasis-directed SBRT: Results from a large international database","volume":"186","author":"Cao","year":"2023","journal-title":"Radiother Oncol"},{"key":"R12-20260203","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/hed.26061","article-title":"Defining a cohort of oligometastatic nasopharyngeal carcinoma patients with improved clinical outcomes","volume":"42","author":"Chee","year":"2020","journal-title":"Head Neck"},{"key":"R13-20260203","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1200\/JCO.2000.18.6.1324","article-title":"Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type","volume":"18","author":"Fandi","year":"2000","journal-title":"J Clin Oncol"},{"key":"R14-20260203","doi-asserted-by":"crossref","first-page":"22091","DOI":"10.1002\/cam4.6816","article-title":"Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma","volume":"12","author":"Lu","year":"2023","journal-title":"Cancer Med"},{"key":"R15-20260203","doi-asserted-by":"crossref","first-page":"107074","DOI":"10.1016\/j.oraloncology.2024.107074","article-title":"Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: a multicenter, retrospective cohort study","volume":"159","author":"He","year":"2024","journal-title":"Oral Oncol"},{"key":"R16-20260203","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2017.02.029","article-title":"Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment","volume":"77","author":"Zou","year":"2017","journal-title":"Eur J Cancer"},{"key":"R17-20260203","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/hed.24345","article-title":"Oligometastases in AJCC stage IVc nasopharyngeal carcinoma: a subset with better overall survival","volume":"38","author":"Tian","year":"2016","journal-title":"Head Neck"},{"key":"R18-20260203","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","article-title":"Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial","volume":"6","author":"You","year":"2020","journal-title":"JAMA Oncol"},{"key":"R19-20260203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.radonc.2017.03.019","article-title":"Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy","volume":"124","author":"Rusthoven","year":"2017","journal-title":"Radiother Oncol"},{"key":"R20-20260203","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.6004\/jnccn.2017.7001","article-title":"Addition of definitive radiotherapy to chemotherapy in patients with newly diagnosed metastatic nasopharyngeal cancer","volume":"15","author":"Verma","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"R21-20260203","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"key":"R22-20260203","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:00:55Z","timestamp":1770141655000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006292"}},"subtitle":["Preliminary Evidence"],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006292","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"2025-08-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}